TIDMPSY
RNS Number : 6748M
Psych Capital PLC
25 May 2022
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN
PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM, THE UNITED STATES
OF AMERICA, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR SOUTH AFRICA
OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS
ANNOUNCEMENT.
This announcement is an advertisement and not an admission
document or a prospectus. This announcement is not and does not
constitute or form part of, and should not be construed as, an
offer of securities for subscription or sale in any jurisdiction
nor a solicitation of any offer to buy or subscribe for, any
securities in any jurisdiction, nor shall it or any part of it, or
the fact of its distribution, form the basis of, or be relied on in
connection with, any contract or commitment whatsoever. This
announcement does not constitute a recommendation regarding any
securities. Prospective investors should not subscribe for or
purchase any securities referred to in this announcement except in
compliance with applicable securities laws and regulation and on
the basis of the information in the final admission document
("Admission Document") intended to be published by Psych Capital
plc, and the proposed admission of the entire issued and to be
issued ordinary share capital of the Company to trading on the AQSE
Growth Market.
Psych Capital Plc
("Psych" or the "Company")
Intention to Float on Aquis
Investing in psychedelics to revolutionise mental health
treatment
Psych Capital Plc, the psychedelic medicines media and
investment company, announces its intention to seek admission of
the entire issued and to be issued ordinary share capital of the
Company to the AQSE Growth Market ("Admission").
Key Highlights
-- The Company currently has exposure to key segments of the
medical psychedelic sector through both strategic acquisitions and
investments, including:
o Clinical research in connection with the development of
psychedelic medicines used to treat addiction;
o Data collection in relation to developments in the psychedelic
sector (including, the legal framework, commerce and science);
and
o Media and communications platform for the medical psychedelic
industry
-- The Company intends to identify, fund and support the
building of future companies across three core pillars: therapeutic
treatments, drug development, and data/artificial intelligence
-- The Company will leverage its portfolio of brands and network
of experts to identify early-stage opportunities in the medical
psychedelic industry
-- The Psych Platform is a global B2B resource for networking,
intelligence and insights, servicing the industry through
publications, newsletters and engaging events
o PSYCH Symposium events generate strong revenue through
sponsorship and ticket sales
Market Opportunity
The market opportunity in the nascent and growing psychedelics'
space is being harnessed by a growing base of institutional
investors seeking to establish and scale businesses in a landscape
showing scientific and commercial promise. While capital invested
in psychedelic companies is over US$2 billion, the current value of
medical businesses surpasses US$10 billion, with ATAI Life
Sciences' initial public offering (IPO) last year which made it the
most valuable publicly-traded business among the 47 publicly-traded
businesses in the sector, currently valued at US$928 million (as of
14 February 2022). Biotech and pharmaceutical companies continue to
dominate businesses within the sector, though there is a growing
base - and appetite for - research clinics, therapy providers and
software infrastructure. (Source: The Psychedelics as Medicine
Report 3rd Edition 2021.)
In modelling the medical psychedelics market, the Company is
focused on therapy training and services, to encapsulate the
current market condition. In 2021, with ketamine the only compound
used off-label widely for the treatment of mental health
conditions, and esketamine for Treatment-Resistant Depression,
ketamine-assisted-therapy dominates the market. The Company expects
compassionate use to increasingly include psilocybin and MDMA, with
policy and health advocates being strong proponents of such
therapies. MDMA is currently available for compassionate use in
Israel, Switzerland and Canada.
Current Platforms and Investments
Investments
Psych has undertaken an investment in Awakn, a Canadian NEO
Exchange listed psychedelics research and clinical group, with
operations in the UK and Europe.
The Company will particularly seek to focus on identifying and
supporting, strategically and financially early-stage companies
that provide ancillary products and services which serve the
medical psychedelic sector, primarily in the UK, across Europe and
other internationally recognised jurisdictions (such as Canada),
which have well-developed and reputable laws and regulations
supporting the research and production of psychedelic
medicines.
Platforms
PSYCH is a business-to-business data, intelligence and media
platform for the psychedelic science and healthcare industry, and
it operates the website, https://psych.global/. PSYCH is a global
B2B resource for data, intelligence and insights, servicing the
industry through publications, newsletters and engaging events.
PSYCH has amassed a significant global B2B audience, with over
20,000 subscribers to the platform.
As a business-to-business media and content platform, the Psych
Platform also produces the PSYCH Symposium, a premium Live Event
series.
PSYCH Symposium
To date PSYCH events have featured over 80 speakers, that
include Professor David Nutt, Christian Angermayer and Rick Doblin,
welcomed 3,000+ delegates and generated strong revenue through
sponsorship and ticket sales.
The PSYCH Symposium, held on Wednesday 11 May 2022 at the
National Gallery was Sold Out. The Symposium attended by over 300
attendees. Further details on the event can be found at:
https://www.psychsymposium.com/ .
The Company is pleased with the success of the event that is
indicative of the support and reach of PSYCH. The success of the
event was a result of the Psych Capital team's commitment and
continued support by a host of sponsors -
https://www.psychsymposium.com/sponsorship - in the psychedelics
sector.
For further information on Psych Capital please visit
https://psych.capital/
Directors
William Christopher Potts (Chief Executive Officer)
William Potts is the co-founder of Psych Capital Plc. He has
been an active investor in psychedelics healthcare since 2020, and
brings an extensive network of high net worth and institutional
investors to the table. William has been specifically focused on
the healthcare sector for a number of years.
Stephen Murphy (Executive Director)
Stephen Murphy is the co-founder of Psych Capital Plc. He is
also the CEO and co-founder of Prohibition Holdings which owns some
of the cannabis industry's best known B2B companies and brands
including Prohibition Partners and Cannabis Europa. Stephen's
background is in technology, digital media and corporate
finance.
Proposed Directors
Joseph Tregonning Colliver (Non-Executive Director )
Joseph built and led a team at one of the UK's first publicly
listed CBD wellness and medicinal cannabis company. Joseph led the
reverse-takeover via a scheme of arrangement of a listed Canadian
CBD wellness business, merging the two companies and listing the
combined group on the CSE and AQSE. In his CFO / COO role he had
accountability for all regulatory matters, leading the company's
novel food application process with the Food Standards Agency,
obtaining a Home Office controlled drugs licence, and liaising with
regulators such as Trading Standards, VMD, MHRA. Joseph had P&L
accountability for the analytical laboratory (achieving ISO 107025)
and wholesale CBD extraction operations and sales in Europe, as
well as finance, HR, legal, fund-raising, investor relations, and
M&A. Joseph was also responsible for the research partnership
with King's College London and recruited and oversaw the Scientific
Advisory Board. Prior to this, Joseph spent 10 years at WPP,
holding senior finance, commercial and client facing leadership
roles across several operating companies, after qualifying as a
chartered accountant in audit practice.
William Potts, Co-founder and CEO of Psych Capital
commented:
"We are excited by the opportunity to capitalise on the rapidly
expanding psychedelic medicines industry. We are particularly well
placed to generate returns as we leverage our knowledge and
experience to provide access and visibility to early stage deals
not usually available to investors. Importantly, we believe that
our experience, philosophy and industry know how sets us apart. We
look forward to beginning this new chapter and highly anticipate
taking advantage of the ever-increasing opportunities available in
this very exciting market."
For further information, please contact:
Psych Capital Plc
Stephen Murphy, Executive via Walbrook PR
Director
Will Potts, Chief Executive
Officer
Walbrook PR Ltd (Media & Tel: +44 (0)20 7933 8780 or psych@walbrookpr.com
Investor Relations)
Nick Rome / Tom Cooper Mob: +44 (0) 7748 325 236 / +44
(0) 7971 221 972
About Psych Capital Plc
Psych Capital Plc identifies, funds and aims to support the
building of British and European companies across three core
pillars: therapeutic treatments, drug development, and data/AI. Its
mission is to support a new wave of innovators who are well
positioned to challenge the status-quo and revolutionise how
society deals with mental health conditions.
Through a network of analysts with deep industry knowledge and
capital markets expertise, Psych Capital is focussed on developing
a rigorously selected portfolio of industry leading companies at
the intersection of psychedelic medicine and technology.
The Psych Platform is a business-to-business media and content
platform for the psychedelic science and healthcare industry, and
it operates the website, https://psych.global/. The Psych Platform
is a global B2B resource for networking, intelligence and insights,
servicing the industry through publications, newsletters and
engaging events. The Psych Platform has amassed a significant
global B2B audience, with over 20,000 subscribers to the
platform.
As a business-to-business media and content platform, the Psych
Platform also produces the PSYCH Symposium, a premium Live Event
series.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXDZLFLLELBBBE
(END) Dow Jones Newswires
May 25, 2022 03:30 ET (07:30 GMT)